Single-Cell Sequencing

Single-Cell Sequencing

Cell therapy products are characterized by high heterogeneity; conventional bulk cell assays are unable to reveal functional differences among cell subpopulations, editing efficiency distribution, or underlying safety risks. GeneRulor's single-cell multi-omics platform resolves product safety and functional profiles at single-cell resolution, providing core data support for precision quality control and mechanistic research. Single-cell transcriptome sequencing (including Perturb-seq) simultaneously records gene perturbation information and transcriptomic responses at the single-cell level, systematically evaluating the impact of gene editing or gene knockdown on cell state, differentiation trajectory, and immune phenotype, and identifying aberrantly activated pro-inflammatory pathways or tumorigenic gene expression signatures. Single-cell DNA sequencing focuses on detecting editing heterogeneity in multi-gene-editing products, revealing the distribution of different editing combinations across the cell population, quantifying mono-allelic, bi-allelic, and unedited cell proportions, and detecting genomic instability events such as large deletions and chromosomal aberrations. Single-cell proteome sequencing (CITE-seq) enables simultaneous quantification of dozens of surface markers and intracellular proteins via antibody barcoding, precisely characterizing the proportions of memory T cells, effector T cells, exhausted T cells, and regulatory T cells in CAR-T and TCR-T products to assess functional potency and safety risks. Single-cell VDJ sequencing focuses on immune receptor diversity analysis, reconstructing TCR/BCR clonotype repertoires and evaluating T or B cell diversity and clonal expansion patterns to monitor potential clonal proliferation risks. The platform integrates multi-omics data for joint analysis and cell atlas construction, providing scientific evidence to support process optimization, clinical efficacy prediction, and safety assessment.